Edgewise Therapeutics, Inc. (EWTX)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $45.04
- As of
Kresmion compiles this page from EWTX's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Edgewise Therapeutics, Inc. (EWTX): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-11-04.
See the full EWTX dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for EWTX on one page. Preview it with sample data, then open it live with a free account.
Preview the EWTX dossierActive events for EWTX
- mediumEarnings below estimates
Q3-2026: Missed consensus by 107.5%, EPS $-0.19 vs $2.5322 estimate
- high13F: funds added
3 tracked funds increased EWTX this 2026Q2, institutional consensus
- high13F: large reduction
CITADEL ADVISORS LLC cut 80% of EWTX (2026Q2)
- high13F: large increase
CITADEL ADVISORS LLC added +109% to EWTX (2026Q2)
- high13F: large increase
CITADEL ADVISORS LLC added +1659% to EWTX (2026Q2)
FREE, NO ACCOUNT
Every event on EWTX, as it fires
You are seeing 5 of 14 events recorded on EWTX since 2026-05-16.
The five above landed across 3 days. The other 9 were recorded on 3 other days. 8 of the 14 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
EWTX positions held by the managers we follow (2026Q2)
What the managers we follow bought and sold in Q2 2026
| Manager / security | Market value | % of reported value |
|---|---|---|
| CITADEL ADVISORS LLC FundCUSIP 28036F105 · 2026Q2 | $19.1M | 0.01% |
| D. E. Shaw & Co., Inc. FundCUSIP 28036F105 · 2026Q2 | $7.7M | 0.00% |
| Point72 Asset Management, L.P. FundCUSIP 28036F105 · 2026Q2 | $4.8M | 0.01% |
| TWO SIGMA INVESTMENTS, LP FundCUSIP 28036F105 · 2026Q2 | $2M | 0.00% |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. The share of reported value is each position's value over the sum of the values that manager reported for the quarter; option lines are not in that sum, as on each fund page. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, EWTX
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
More data on EWTX
Related tickers
Cite this data
Kresmion counts the managers it follows that reported a non-option position in EWTX on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on EWTX in the last 180 days.
Upstream: SEC EDGAR filings for EWTX
Kresmion, "Edgewise Therapeutics, Inc. (EWTX) institutional holdings and SEC filings", data as of 2026-11-08, https://kresmion.com/research/EWTX. Upstream data: SEC EDGAR filings for EWTX.
Link to this data (HTML):
<a href="https://kresmion.com/research/EWTX">Edgewise Therapeutics, Inc. (EWTX) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow EWTX on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to EWTX for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.